M
MONOPAR THERAPEUTICS INC
NASDAQ: MNPR (Monopar Therapeutics Inc.)
最近更新时间: 7分钟之前55.54
-0.73 (-1.29%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Monopar Therapeutics Inc. | 看跌 | 看涨 |
AIStockmoo 评分
0.1
| 分析师共识 | 1.0 |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -5.0 |
| 平均 | 0.13 |
|
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 34.38% |
| 机构持股比例 | 47.24% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 115.00 (Morgan Stanley, 107.08%) | 购买 |
| 中 | 104.00 (87.27%) | |
| 低 | 100.00 (Chardan Capital, 80.07%) | 购买 |
| 平均值 | 106.33 (91.47%) | |
| 总计 | 3 购买 | |
| 平均价格@调整类型 | 62.05 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| BTIG | 23 Feb 2026 | 104.00 (87.27%) | 购买 | 55.80 |
| 02 Feb 2026 | 104.00 (87.27%) | 购买 | 65.48 | |
| Chardan Capital | 29 Jan 2026 | 100.00 (80.07%) | 购买 | 67.34 |
| Morgan Stanley | 09 Jan 2026 | 115.00 (107.08%) | 购买 | 63.00 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合